Alkermes plc (ALKS) Implied Volatility Current

Tracking ALKS implied volatility helps you identify when options premiums on Alkermes plc are historically cheap or expensive, and where the best trades are hiding. Alkermes plc implied volatility reflects the market's expectation of future price movement: when ALKS IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Alkermes plc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For ALKS, tracking metrics like ALKS IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on ALKS signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases.

The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where ALKS implied volatility sits today versus where it has been. Our scanner ranks Alkermes plc implied volatility against its historical range, surfaces extremes in ALKS IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Alkermes plc IV is rich or cheap — measure it, then act on it.